Fabino Enterprises
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures · TTM
- ROCE
- −10.70%
- Debt to Equity
- 0.44
- EPS (TTM)
- ₹0.10
- Book Value
- ₹17.36
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- —
- ROE
- −14.30%
- Dividend Yield
- 0.00%
- EBITDA
- −₹50.00 L
- 52W High
- —
- 52W Low
- —
Key Insights
Strengths
1- Stock is trading at 1.17 times its book value
Weaknesses
3- Company has low interest coverage ratio.
- Company has a low return on equity of -3.76% over last 3 years.
- Company has high debtors of 288 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 9 | 3 | 7 |
| Oscillators | Bearish | 4 | 3 | 2 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bearish
Overall
Bearish
Moving Averages
Neutral
Key readings
- RSI (14)
- 60.09
- Neutral
- MACD (12,26,9)
- −0.47
- Bullish
- SMA (50)
- 21.18
- Bearish
- SMA (200)
- 27.35
- Bearish
As of , the latest day with price data, so these readings are not current.
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +83.70% |
|---|---|
| 1Y | +15.85% |
Net profit
| 3Y | Turned to loss |
|---|---|
| 1Y | Turned to loss |
Operating cash flow
| 3Y | Turned positive |
|---|---|
| 1Y | +58.33% |
Operating margin· change in pp
| 3Y | −10.73 pp |
|---|---|
| 1Y | −10.45 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2023 | ₹3.36 Cr |
|---|---|
| Mar 2024 | ₹21.01 Cr |
| Mar 2025 | ₹17.98 Cr |
| Mar 2026 | ₹20.83 Cr |
Net profit by year
| Mar 2023 | ₹0.01 Cr |
|---|---|
| Mar 2024 | ₹0.04 Cr |
| Mar 2025 | ₹0.06 Cr |
| Mar 2026 | −₹0.56 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 2.32 | 12.86 | 8.22 | 4.25 | 13.78 | 6.63 | 14.21 |
| Expenses | 2.3 | 12.74 | 8.23 | 4.22 | 13.7 | 6.95 | 15.96 |
| Operating Profit | 0.02 | 0.12 | −0.01 | 0.03 | 0.08 | −0.32 | −1.75 |
| OPM % | 0.86% | 0.93% | −0.12% | 0.71% | 0.58% | −4.83% | −12.32% |
| Other Income | 0 | 0.01 | 0 | 0.11 | 0.18 | 0.28 | 1.29 |
| Interest | 0 | 0 | 0.03 | 0.06 | 0.07 | 0.09 | 0.04 |
| Depreciation | 0.02 | 0.01 | 0.03 | 0.04 | 0.04 | 0.06 | 0.05 |
| PBT | 0 | 0.12 | −0.07 | 0.04 | 0.15 | −0.19 | −0.55 |
| Tax % | — | 25% | −28.57% | 25% | 80% | 0% | −32.73% |
| Net Profit | 0 | 0.09 | −0.05 | 0.03 | 0.03 | −0.19 | −0.37 |
| EPS (₹) | 0 | 0.43 | −0.24 | 0.14 | 0.14 | −0.9 | −1.76 |
Profit & Loss
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 3.36 | 21.01 | 17.98 | 20.83 |
| Expenses | 3.33 | 20.89 | 17.87 | 22.88 |
| Operating Profit | 0.03 | 0.12 | 0.11 | −2.05 |
| OPM % | 0.89% | 0.57% | 0.61% | −9.84% |
| Other Income | 0.02 | 0.01 | 0.29 | 1.56 |
| Interest | 0.01 | 0.04 | 0.13 | 0.14 |
| Depreciation | 0.03 | 0.04 | 0.08 | 0.11 |
| PBT | 0.01 | 0.05 | 0.19 | −0.74 |
| Tax % | 0% | 20% | 68.42% | −24.32% |
| Net Profit | 0.01 | 0.04 | 0.06 | −0.56 |
| EPS (₹) | 0.05 | 0.19 | 0.29 | −2.67 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 2.1 | 2.1 | 2.1 | 2.1 |
| Reserves | 2.01 | 2.04 | 2.1 | 1.55 |
| Borrowings | 0.41 | 1.27 | 1.79 | 1.62 |
| Other Liabilities | 0.5 | 9.95 | 11.67 | 16.87 |
| Total Liabilities | 5.02 | 15.36 | 17.66 | 22.14 |
| Fixed Assets | 0.15 | 0.34 | 0.55 | 0.37 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 4.87 | 15.02 | 17.11 | 21.77 |
| Total Assets | 5.02 | 15.36 | 17.66 | 22.14 |
Cash Flow
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | −0.68 | −0.77 | 0.12 | 0.19 |
| Investing | −0.01 | −0.28 | −0.29 | 0.07 |
| Financing | 0.34 | 0.86 | 0.35 | −0.3 |
| Net Cash Flow | −0.35 | −0.18 | 0.18 | −0.05 |
| Free Cash Flow | −0.69 | −1.01 | −0.17 | 0.26 |
| CFO/EBITDA | −2,233 | −633 | 227 | −9 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 275 | 219 | 288 | 288 |
| Inventory Days | 147 | 24.21 | 26.56 | 19.14 |
| Days Payable | 45.78 | 179 | 253 | 297 |
| Cash Conversion Cycle | 376 | 63.97 | 61.44 | 10.12 |
| Working Capital Days | 444 | 86.34 | 104 | 78.33 |
| ROCE % | — | 1.81% | 5.61% | −10.66% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fabino Enterprises insights
55 extracted metrics across FY22–FY26.
Documents
- 28 May 2024
- General announcements 21 Oct 2026
- Intimation For Reclassification Of Shareholding Under Regulation 31A Of SEBI (LODR) Regulations 2015General announcements 19 Oct 2026
Frequently Asked Questions about Fabino Enterprises
What does Fabino Enterprises Ltd do?
Where is Fabino Enterprises Ltd (FABINO) listed?
Which sector does Fabino Enterprises Ltd belong to?
What is the Return on Equity (ROE) of Fabino Enterprises Ltd?
Company Information
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543444.md for Fabino Enterprises Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.